Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 247

Sort by

Sort Order Select

Journal Articles

Baseline Characteristics from Arise Study, an Italian Non-Interventional Study Assessing the Real-World Use of Acalabrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2024) 144 (Supplement 1): 7747.

https://doi.org/10.1182/blood-2024-199041

Published: 2024

Journal Articles

Advancing Diagnostic Accuracy and Lowering Idiopathic Erythrocytosis Rates through Next-Generation Sequencing

Davide Pio Abagnale, Ugo De Martino, Roberta Russo, Raffaella Iannotta, Fabrizio Pane, Novella Pugliese

Blood (2024) 144 (Supplement 1): 2463.

https://doi.org/10.1182/blood-2024-210893

Published: 2024

Journal Articles

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Nico Gagelmann, Barbara Mora, Filippo Branzanti, Alessandro Maria Vannucchi, Massimo Breccia, Giuseppe Alberto Maria Palumbo, Massimiliano Bonifacio, Erika Morsia, Elena Maria Elli, Mario Tiribelli, Giulia Benevolo, Mirko Farina, Fabrizio Pane, Roberto Massimo Lemoli, Giovanni Caocci, Alessia Tieghi, Gianni Binotto, Francesco Cavazzini, Bruno Martino, Alessandro Isidori, Margherita Maffioli, Elisa Rumi, Tiziano Barbui, Francisco Cervantes, Matteo Giovanni Della Porta, Andrew T. Kuykendall, Marianna Caramella, Alessandra Iurlo, Valerio De Stefano, Jean-Jacques Kiladjian, David Ross, Jason Gotlib, Timothy Devos, Marco Ruggeri, Richard T. Silver, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Christina Rautenberg, Marie Robin, Marie-Thérèse Rubio, Jaroslaw Maciejewski, Alessandro Rambaldi, Maria Chiara Finazzi, Andrea Bacigalupo, Patrizia Chiusolo, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kröger, Francesco Passamonti, Francesca Palandri

Blood (2024) 144 (Supplement 1): 245.

https://doi.org/10.1182/blood-2024-210804

Published: 2024

Journal Articles

Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome

Blood (2024) 144 (Supplement 1): 2690.

https://doi.org/10.1182/blood-2024-194413

Published: 2024

Journal Articles

Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network

Blood (2024) 144 (Supplement 1): 992.

https://doi.org/10.1182/blood-2024-210201

Published: 2024

Journal Articles

Long-Term Safety and Effectiveness of Ponatinib Treatment in Patients with TKI Intolerance: Subgroup Analysis of the Observational Study of Ponatinib Treatment in Patients with CML in Italy (OITI)

Massimo Breccia, Alessandra Iurlo, Fabrizio Pane, Anna Rita Scortechini, Immacolata Attolico, Marco Santoro, Marco Cerrano, Francesca Lunghi, Alessandro Maggi, Nicola Di Renzo, Valeria Sargentini, Alfonso Piciocchi, Claudia Tringali, Alessandra Malato

Blood (2024) 144 (Supplement 1): 2427.

https://doi.org/10.1182/blood-2024-200389

Published: 2024

Journal Articles

Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study

Alfonso Piciocchi, Giovanni Marsili, Ylenia Belperio, Monica Messina, Francesca Paola Paoloni, Stefano Soddu, Isabella Capodanno, Rosaria Sancetta, Elisabetta Abruzzese, Alessandro Pulsoni, Monia Lunghi, Giovanni Caocci, Fausto Castagnetti, Paola Fazi, Marco Vignetti, Massimo Breccia, Fabrizio Pane

Blood (2024) 144 (Supplement 1): 4530.

https://doi.org/10.1182/blood-2024-198366

Published: 2024

Journal Articles

Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network

Blood (2024) 144 (Supplement 1): 4535.

https://doi.org/10.1182/blood-2024-202477

Published: 2024

Journal Articles

A Study on the Effect of Luspatercept on Regulatory T Cells and Myeloid Derived Suppressor Cells in Low Risk Myelodysplastic Syndrome with Ring Sideroblasts

Stefania Leone, Francesco Grimaldi, Mara Memoli, Flavia Carriero, Giulia Scalia, Annamaria Vincenzi, Giuseppe Cerciello, Fabrizio Pane, Alessandra Picardi, Giuseppe Terrazzano, Giuseppina Ruggiero, Valentina Rubino

Blood (2024) 144 (Supplement 1): 1809.

https://doi.org/10.1182/blood-2024-210766

Published: 2024

Journal Articles

ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial

Blood (2024) 144 (Supplement 1): 3158.

https://doi.org/10.1182/blood-2024-205465

Published: 2024

Journal Articles

First-Line Daratumumab-Based Regimens in Multiple Myeloma Patients Aged 65-70 Years: A Pilot Real-World Study on Efficacy and Safety

Salvatore Palmieri, Roberta Della Pepa, Stefano Rocco, Raffaella Reina, Giuseppe Gaeta, Novella Pugliese, Aldo Leone, Fabio Trastulli, Angela Gravetti, Maria Celentano, Mariangela Pedata, Francesco Grimaldi, Fabrizio Pane, Mario Annunziata

Blood (2024) 144 (Supplement 1): 7073.

https://doi.org/10.1182/blood-2024-210292

Published: 2024

Journal Articles

Cytopenias and Failure to Use Innovative Therapy Are Main Drivers of Worse Outcome after Discontinuation of Ruxolitinib in Myelofibrosis

Blood (2024) 144 (Supplement 1): 6664.

https://doi.org/10.1182/blood-2024-199961

Published: 2024

Journal Articles

Real-World Use and Outcome of Ropeginterferon ALFA-2B in Polycythemia VERA Patients: A Multicenteric Study

Novella Pugliese, Maria Di Perna, Ugo De martino, Valeria Amico, Mario Annunziata, Maria Carmen Martorelli, Davide Pio Abagnale, Roberta Russo, Maria Ferrentino, Alessia Scarpa, Francesco Muriano, Vincenzo Martinelli, Fabrizio Pane

Blood (2024) 144 (Supplement 1): 6651.

https://doi.org/10.1182/blood-2024-210785

Published: 2024

Journal Articles

CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

Blood (2024) 144 (Supplement 1): 3155.

https://doi.org/10.1182/blood-2024-207877

Published: 2024

Journal Articles

Treatment of Chronic ITP with Avatrombopag: A Multicentric Real-World Experience

Mario Troiano, Claudia Giordano, Elena Rossi, Potito Rosario Scalzulli, Laura Mettivier, Alessandro D'Ambrosio, Daniele Mazzoni, Erika Vatiero, Carmine Selleri, Fabrizio Pane, Ferdinando Frigeri

Blood (2024) 144 (Supplement 1): 5446.

https://doi.org/10.1182/blood-2024-210230

Published: 2024

Journal Articles

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

Blood (2023) 142 (Supplement 1): 826.

https://doi.org/10.1182/blood-2023-174973

Published: 2023

Journal Articles

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Blood (2023) 142 (Supplement 1): 3178.

https://doi.org/10.1182/blood-2023-188305

Published: 2023

Journal Articles

Full Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study

Alessandra Iurlo, Massimo Breccia, Fabio Stagno, Elisabetta Abruzzese, Fabrizio Pane, Immacolata Attolico, Paolo Sportoletti, Marco Cerrano, Sara Galimberti, Barbara Scappini, Maurizio Miglino, Sergio Siragusa, Isabella Capodanno, Diletta Valsecchi, Aurelio Pio Nardozza, Alessandra Misto, Paola Coco, Giuseppe Saglio, Gianantonio Rosti

Blood (2023) 142 (Supplement 1): 4534.

https://doi.org/10.1182/blood-2023-180131

Published: 2023

Journal Articles

International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia (SUSTRENIM trial): Analysis of the Eligibility to Treatment Discontinuation

Blood (2023) 142 (Supplement 1): 3169.

https://doi.org/10.1182/blood-2023-182220

Published: 2023

Journal Articles

The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 nd Generation TKIs

Blood (2023) 142 (Supplement 1): 3168.

https://doi.org/10.1182/blood-2023-182981

Published: 2023

NARROW

Baseline Characteristics from Arise Study, an Italian Non-Interventional Study Assessing the Real-World Use of Acalabrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Advancing Diagnostic Accuracy and Lowering Idiopathic Erythrocytosis Rates through Next-Generation Sequencing

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome

Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network

Long-Term Safety and Effectiveness of Ponatinib Treatment in Patients with TKI Intolerance: Subgroup Analysis of the Observational Study of Ponatinib Treatment in Patients with CML in Italy (OITI)

Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study

Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network

A Study on the Effect of Luspatercept on Regulatory T Cells and Myeloid Derived Suppressor Cells in Low Risk Myelodysplastic Syndrome with Ring Sideroblasts

First-Line Daratumumab-Based Regimens in Multiple Myeloma Patients Aged 65-70 Years: A Pilot Real-World Study on Efficacy and Safety

Cytopenias and Failure to Use Innovative Therapy Are Main Drivers of Worse Outcome after Discontinuation of Ruxolitinib in Myelofibrosis

Real-World Use and Outcome of Ropeginterferon ALFA-2B in Polycythemia VERA Patients: A Multicenteric Study

CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

Treatment of Chronic ITP with Avatrombopag: A Multicentric Real-World Experience

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Full Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study

International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia (SUSTRENIM trial): Analysis of the Eligibility to Treatment Discontinuation

The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 nd Generation TKIs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only